Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.38 USD | -5.48% | -15.85% | -10.97% |
Financials (USD)
Sales 2024 * | 103M | Sales 2025 * | 76.06M | Capitalization | 108M |
---|---|---|---|---|---|
Net income 2024 * | -12M | Net income 2025 * | -50M | EV / Sales 2024 * | 1.04 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.41 x |
P/E ratio 2024 * |
-9.74
x | P/E ratio 2025 * |
-2.92
x | Employees | 121 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.97% |
Latest transcript on CytomX Therapeutics, Inc.
1 day | -5.48% | ||
1 week | -15.85% | ||
Current month | -18.82% | ||
1 month | -28.87% | ||
3 months | -33.01% | ||
6 months | -6.12% | ||
Current year | -10.97% |
Managers | Title | Age | Since |
---|---|---|---|
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Chris Ogden
DFI | Director of Finance/CFO | 40 | 21-08-01 |
Marcia Belvin
CTO | Chief Tech/Sci/R&D Officer | 57 | 17-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Meyers
BRD | Director/Board Member | 59 | 18-12-19 |
Elaine Jones
BRD | Director/Board Member | 69 | 14-11-30 |
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-14 | 1.38 | -5.48% | 1,635,319 |
24-06-13 | 1.46 | -2.01% | 1,501,641 |
24-06-12 | 1.49 | 0.00% | 4,740,840 |
24-06-11 | 1.49 | -8.59% | 6,095,641 |
24-06-10 | 1.63 | -0.61% | 2,255,493 |
Delayed Quote Nasdaq, June 14, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.97% | 108M | |
+18.15% | 124B | |
+18.02% | 112B | |
-12.75% | 22.22B | |
+5.07% | 22.94B | |
-39.94% | 16.87B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- CTMX Stock